Skip to Main Content

Advertisement

Skip Nav Destination

Abstract 4663: Combination of c-Met inhibitor tepotinib (MSC2156119J) and a third-generation EGFR inhibitor can overcome double resistance mediated by EGFR T790M mutation and c-Met amplification in non-small cell lung cancer models

Cancer Res (2016) 76 (14_Supplement): 4663.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal